MAHIDOL UNIVERSITY Patent applications |
Patent application number | Title | Published |
20140141040 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. | 05-22-2014 |
20120021936 | BIOMARKERS FOR DENGUE - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying dengue status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with dengue or not infected with dengue. The biomarkers can be detected by SELDI mass spectrometry. | 01-26-2012 |
20120014981 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. | 01-19-2012 |
20110301043 | RISK ASSESSMENT FOR CUTANEOUS ADVERSE DRUG REACTIONS FROM ANTIRETROVIRAL AGENT - The present invention provides a method of predicting the risk of a patient for developing cutaneous adverse drug reaction to non-nucleoside reverse transcriptase inhibitors such as nevirapine by using HLA-B*3505 allele and/or polymorphisms in the CCHCR1 gene. | 12-08-2011 |